Form 8-K - Current report:
SEC Accession No. 0001193125-25-335410
Filing Date
2025-12-29
Accepted
2025-12-29 16:30:25
Documents
12
Period of Report
2025-12-24
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rkda-20251224.htm   iXBRL 8-K 55834
2 EX-99.1 rkda-ex99_1.htm EX-99.1 16210
3 GRAPHIC img192114479_0.jpg GRAPHIC 9353
  Complete submission text file 0001193125-25-335410.txt   220861

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rkda-20251224.xsd EX-101.SCH 44849
14 EXTRACTED XBRL INSTANCE DOCUMENT rkda-20251224_htm.xml XML 4671
Mailing Address 5956 SHERRY LANE SUITE 2000 DALLAS TX
Business Address 5956 SHERRY LANE SUITE 2000 DALLAS TX 214-974-8921
Arcadia Biosciences, Inc. (Filer) CIK: 0001469443 (see all company filings)

EIN.: 810571538 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37383 | Film No.: 251609564
SIC: 1311 Crude Petroleum & Natural Gas
(CF Office: 01 Energy & Transportation)